Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Expert Opinion on Drug Metabolism & Toxicology

• Publication date

  2008-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1517/17425255.4.2.137PMID 18248309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of an inflammation‐based prognostic score (GPS) with performance status (ECOG‐ps) in patients receiving palliative chemotherapy for gastroesophageal cancer

  2008cited by this paper
• The adaptive immunologic microenvironment in colorectal cancer: a novel perspective.

  2007cited by this paper
• Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer

  2007cited by this paper
• Preoperative but not postoperative systemic inflammatory response correlates with survival in colorectal cancer

  2007cited by this paper
• Pharmacogenomic (PG) analysis of Japan-SWOG common arm study in advanced stage non-small cell lung cancer (NSCLC): A model for testing population-related pharmacogenomics

  2007cited by this paper
• Transcriptional regulation and expression of CYP3A4 in hepatocytes.

  2007cited by this paper
• Imatinib Disposition and ABCB1 (MDR1, P‐Glycoprotein) Genotype

  2007cited by this paper
• Circulating biomarkers for prostate cancer

  2007cited by this paper
• Regulation of drug transporters during infection and inflammation.

  2007cited by this paper
• Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes

  2007influential reference
• A cytokine-mediated link between innate immunity, inflammation, and cancer.

  2007cited by this paper
• Significance of interleukin-6 (IL-6) in breast cancer (review)

  2007cited by this paper
• Diagnostic Utility of Interleukin-6 (IL-6) for Primary Bile Duct Cancer and Changes in Serum IL-6 Levels Following Photodynamic Therapy

  2007cited by this paper
• Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer

  2007cited by this paper
• The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer

  2006cited by this paper
• Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

  2006cited by this paper
• Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms

  2006cited by this paper
• Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer

  2006cited by this paper
• Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma.

  2006cited by this paper
• The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder

  2006cited by this paper
• The erythromycin breath test reflects P‐glycoprotein function independently of cytochrome P450 3A activity

  2006cited by this paper
• Transcriptional Repression of Hepatic Cytochrome P450 3A4 Gene in the Presence of Cancer

  2006cited by this paper
• Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study.

  2006cited by this paper
• The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer

  2006cited by this paper
• Evaluation of Nutritional and Inflammatory Status of Advanced Colorectal Cancer Patients and Its Correlation With Survival

  2006cited by this paper
• Nuclear export of retinoid X receptor alpha in response to interleukin-1beta-mediated cell signaling: roles for JNK and SER260.

  2006influential reference
• IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.

  2006cited by this paper
• Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.

  2006cited by this paper
• Evaluation of an inflammation‐based prognostic score in patients with metastatic renal cancer

  2006cited by this paper
• Cytokines in breast cancer.

  2006cited by this paper
• Evaluation of an Inflammation-Based Prognostic Score in Patients with Inoperable Pancreatic Cancer

  2006cited by this paper
• Cytochrome P450 pharmacogenetics and cancer

  2006cited by this paper
• Cytochrome P450 and anticancer drugs.

  2006cited by this paper
• Exploring the Relationship Between Expression of Cytochrome P450 Enzymes and Gefitinib Pharmacokinetics

  2006cited by this paper
• Pharmacogenetics of irinotecan metabolism and transport: an update.

  2006cited by this paper
• Regulation of drug-metabolizing enzymes and transporters in inflammation.

  2006cited by this paper
• Nuclear Export of Retinoid X Receptor α in Response to Interleukin-1β-mediated Cell Signaling

  2006cited by this paper
• The Involvement of the Pregnane X Receptor in Hepatic Gene Regulation during Inflammation in Mice

  2005cited by this paper
• Interleukin-6 polymorphism is associated with more aggressive prostate cancer.

  2005cited by this paper
• Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism.

  2005cited by this paper
• Drug metabolism and variability among patients in drug response.

  2005cited by this paper
• Transcriptional Regulation of the Human Hepatic CYP3A4: Identification of a New Distal Enhancer Region Responsive to CCAAT/Enhancer-Binding Protein β Isoforms (Liver Activating Protein and Liver Inhibitory Protein)

  2005influential reference
• Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel

  2005cited by this paper
• Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer.

  2005cited by this paper
• Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.

  2005cited by this paper
• Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C.

  2005cited by this paper
• Smoldering and polarized inflammation in the initiation and promotion of malignant disease.

  2005cited by this paper
• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005cited by this paper
• Inflammation and cancer: the long reach of Ras

  2005cited by this paper
• Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients

  2005cited by this paper
• Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin’s lymphoma

  2005cited by this paper
• Hepatic Cytochrome P450 Gene Regulation during Endotoxin-Induced Inflammation in Nuclear Receptor Knockout Mice

  2005influential reference
• Nuclear receptors and drug disposition gene regulation.

  2005cited by this paper
• The systemic inflammatory response predicts overall and cancer specific survival in patients with malignant lymphoma.

  2005cited by this paper
• The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer

  2005cited by this paper
• C-Reactive Protein as a Prognostic Variable That Reflects Uncontrolled Up-Regulation of the IL-1-IL-6 Network System in Colorectal Carcinoma

  2004cited by this paper
• Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients

  2004cited by this paper
• The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer

  2004cited by this paper
• Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas

  2004cited by this paper
• Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects

  2004cited by this paper
• Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials.

  2004cited by this paper
• Pharmacogenetics – five decades of therapeutic lessons from genetic diversity

  2004cited by this paper
• Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity

  2004cited by this paper
• Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states

  2004cited by this paper
• Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.

  2004cited by this paper
• Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.

  2004cited by this paper
• Cytochrome P450 and liver diseases.

  2004cited by this paper
• Endotoxin leads to rapid subcellular re-localization of hepatic RXRα: A novel mechanism for reduced hepatic gene expression in inflammation

  2004influential reference
• Feed-forward Regulation of Bile Acid Detoxification by CYP3A4

  2004cited by this paper
• Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene.

  2004cited by this paper
• CAR: detailing new models.

  2004cited by this paper
• CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers

  2004cited by this paper
• AMP-activated Protein Kinase Regulates HNF4α Transcriptional Activity by Inhibiting Dimer Formation and Decreasing Protein Stability*

  2003cited by this paper
• Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.

  2003cited by this paper
• Inheritance and drug response.

  2003cited by this paper
• Predicting inductive drug-drug interactions.

  2003cited by this paper
• Baseline Nutritional Assessment in Advanced Cancer Patients Receiving Palliative Chemotherapy

  2003cited by this paper
• Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response.

  2002influential reference
• Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.

  2002cited by this paper
• Down‐regulation of human CYP3A4 by the inflammatory signal interleukin 6: molecular mechanism and transcription factors involved

  2002cited by this paper
• Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response

  2002cited by this paper
• Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor.

  2002cited by this paper
• Dosing strategies for anticancer drugs: the good, the bad and body-surface area.

  2002cited by this paper
• Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.

  2002cited by this paper
• Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin‐6 as independent predictors of prognosis in aggressive non‐Hodgkin's lymphoma

  2002cited by this paper
• Regulation of hepatic cytochrome P450 2C11 via cAMP: implications for down-regulation in diabetes, fasting, and inflammation.

  2001cited by this paper
• Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3.

  2001cited by this paper
• Regulation of cytochrome p450 by inflammatory mediators: why and how?

  2001cited by this paper
• Gene transcription in hepatocytes during the acute phase of a systemic inflammation: from transcription factors to target genes

  2001cited by this paper
• Transcriptional Control of Intestinal Cytochrome P-4503A by 1 (cid:1) ,25-Dihydroxy Vitamin D 3

  2001cited by this paper
• The Erythromycin Breath Test For the Prediction of Drug Clearance

  2001cited by this paper
• Optimizing the erythromycin breath test for use in cancer patients.

  2000cited by this paper
• Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol.

  2000cited by this paper
• Stress Pathway Activation Induces Phosphorylation of Retinoid X Receptor*

  2000cited by this paper
• Humanized xenobiotic response in mice expressing nuclear receptor SXR

  2000cited by this paper
• Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes.

  2000cited by this paper
• The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module.

  1999cited by this paper
• 6alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes.

  1999cited by this paper
• Cytochrome P-450 3A4: regulation and role in drug metabolism.

  1999cited by this paper
• 6α-Hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes

  1999cited by this paper

• Identification of Enhanced Cyclooxygenase-2 (COX-2) Inhibitors Beyond Curcumin Through Virtual Screening to Target Inflammation-Related Metabolic Complications.

  2026cites this paper
• Pathological and therapeutic roles of bile acid metabolism and signaling in hepatocellular carcinoma: Insights from human and mouse studies.

  2025cites this paper
• Sexual Dimorphism in Cardiometabolic Diseases: From Development to Senescence and Therapeutic Approaches

  2025cites this paper
• Spectrum of blood viscosity, albumin/fibrinogen ratio, and red cell distribution width in newly diagnosed multiple myeloma patients: an observational study

  2025cites this paper
• Anticonvulsant Effects of Synthetic N-(3-Methoxybenzyl)oleamide and N-(3-Methoxybenzyl)linoleamide Macamides: An In Silico and In Vivo Study

  2025cites this paper
• Antimycobacterial Drugs as a Novel Strategy to Inhibit Pseudomonas aeruginosa Virulence Factors and Combat Antibiotic Resistance: A Molecular Simulation Study

  2024cites this paper
• Inhibitory effects characteristics of polysaccharide of Polygonati Rhizome on cytochrome P450 enzymes

  2024cites this paper
• The relation between inflammatory biomarkers and drug pharmacokinetics in the critically ill patients: a scoping review

  2024cites this paper
• Triptolide-induced acute liver injury and its mechanism with estradiol in regulating macrophage-mediated inflammation and hepatocyte function.

  2024cites this paper
• Cellular and molecular aspects of drug resistance in cancers

  2024cites this paper
• Antidepressants as new endocrine disruptors? - transcriptomic profiling in gonads of Mytilus trossulus exposed to norfluoxetine.

  2024cites this paper
• Роль полиморфных вариантов генов цитохромов Р450, а также генов GSTP1 и MDR1 в развитии токсических осложнений при проведении программной противоопухолевой лекарственной терапии у пациентов с классической лимфомой Ходжкина

  2024cites this paper
• CYP4F12 is a potential biomarker and inhibits cell migration of head and neck squamous cell carcinoma via EMT pathway

  2023cites this paper
• Multi-targeting of virulence factors of P. aeruginosa by β-lactam antibiotics to combat antimicrobial resistance

  2023cites this paper
• Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy

  2023cites this paper
• Vascularized Hepatocellular Carcinoma on a Chip to Control Chemoresistance through Cirrhosis, Inflammation and Metabolic Activity

  2023cites this paper
• Plant-derived Antiviral Compounds as Potential COVID-19 Drug Candidates: In-silico Investigation in Search of SARS-CoV-2 Inhibitors

  2023cites this paper
• Correlated downregulation of VDR and CYP3A4 in colorectal cancer

  2022cites this paper
• Pharmacophore Analysis of Monoterpene Melaleuca leucadendra as an Inhibitor for 3CLPro of the SARS-CoV-2

  2022cites this paper
• A commentary on the use of pharmacoenhancers in the pharmaceutical industry and the implication for DMPK drug discovery strategies

  2022cites this paper
• RGD density along with substrate stiffness regulate hPSC hepatocyte functionality through YAP signalling.

  2022cites this paper
• Cirrhosis and Inflammation Regulates CYP3A4 Mediated Chemoresistance in Vascularized Hepatocellular Carcinoma-on-a-chip

  2022cites this paper
• The Role of CYP3A in Health and Disease

  2022cites this paper
• In vitro effects and in silico analysis of newly synthetized pyrrole derivatives on the activity of different isoforms of Cytochrome P450: CYP1A2, CYP2D6 and CYP3A4

  2022cites this paper
• Managing Cancer Drug Resistance from the Perspective of Inflammation

  2022cites this paper
• Antibacterial activity and molecular studies of non-symmetric POCOP-Pd(II) pincer complexes derived from 2,4-dihydroxybenzaldehyde (2,4-DHBA)

  2022cites this paper
• Influence of serum inflammatory cytokines on cytochrome P450 drug metabolising activity during breast cancer chemotherapy: a patient feasibility study

  2021cites this paper
• Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity

  2021cites this paper
• Development of a Sensitive and High-Throughput Assay for Simultaneous Quantification of 5 Tyrosine Kinase Inhibitors and 2 Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry

  2021cites this paper
• CYP3A Activity in End-of-Life Cancer Patients Measured by 4β-Hydroxycholesterol/cholesterol Ratio, in Men and Women

  2021cites this paper
• Pretreatment Platelet Count and Neutrophil/Lymphocyte Ratio Are Predictive Markers for Carboplatin Plus Pemetrexed Therapy-induced Thrombocytopenia

  2021cites this paper
• Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature

  2021cites this paper
• CYP3A4*2 Gene Polymorphism and its association with Clinical Phenotyping (temperament) Concept of Unani Medicine Philosophy in Indian Population

  2021cites this paper
• Severe hypoglycaemia under abemaciclib administration in a patient with breast cancer: A case report

  2021cites this paper
• Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19

  2021cites this paper
• A Search of COVID-19 main Protease Inhibitor from Plant Derived Alkaloids using Chloroquine and Hydroxychloroquine as Reference: An In-silico Approach

  2020cites this paper
• Disrupted hepatic pentose phosphate pathway directly participates in and indirectly promotes CYP3A reduction: A new strategy for CYP3A‐mediated drug hepatotoxicity

  2020cites this paper
• Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno‐Oncology and Beyond: Challenges, Perspectives, and Prospects

  2020cites this paper
• Pathophysiological mechanisms explaining poor clinical outcome of older cancer patients with low skeletal muscle mass

  2020cites this paper
• Gender factor in hematopoietic stem cell transplantation

  2020cites this paper
• Handgrip strength is a comorbidity marker in systemic necrotizing vasculitides and predicts the risk of fracture and serious adverse events.

  2020cites this paper
• Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes

  2020cites this paper
• Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity.

  2019cites this paper
• Xenobiotic receptors in mediating the effect of sepsis on drug metabolism

  2019cites this paper
• Successful prediction of human pharmacokinetics after oral administration by optimized physiologically-based pharmacokinetics approach and permeation assay using human induced pluripotent stem cell-derived intestinal epithelial cells.

  2019cites this paper
• Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment

  2019cites this paper
• Effect of cardiopulmonary bypass on cytochrome P450 enzyme activity: implications for pharmacotherapy

  2018cites this paper
• Profiling of hepatic metabolizing enzymes and nuclear receptors in rats with adjuvant arthritis by targeted proteomics

  2018cites this paper
• Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma

  2018cites this paper
• The Role of Cytochromes P450 in Infection

  2018cites this paper
• The Molecular Interface Between the SUMO and Ubiquitin Systems.

  2017cites this paper
• Aprepitant and fosaprepitant drug interactions: a systematic review

  2017cites this paper
• Predictive factors for sorafenib-induced hand-foot skin reaction using ordered logistic regression analysis.

  2016cites this paper
• Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment

  2016cites this paper
• Single-Walled Carbon Nanotubes Inhibit the Cytochrome P450 Enzyme, CYP3A4

  2016cites this paper
• Score of liver ultrasonography predicts treatment-related severe neutropenia and neutropenic fever in induction chemotherapy with docetaxel for locally advanced head and neck cancer patients with normal serum transamines

  2016cites this paper
• Pharmacological and Interventional Approaches for Optimizing Taxane Treatment

  2016cites this paper
• Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies

  2016cites this paper
• Compelling Relationship of CYP3A Induction to Levels of the Putative Biomarker 4β‐Hydroxycholesterol and Changes in Midazolam Exposure

  2016cites this paper
• Biomarkers in Metastatic Colorectal Cancer

  2015cites this paper
• Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib

  2015cites this paper
• Inter-patient variability in docetaxel pharmacokinetics: A review.

  2015cites this paper
• Understanding Disease–Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window

  2015cites this paper
• Cancer, Inflammation, and Therapy: Effects on Cytochrome P450–Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents

  2014cites this paper
• Cancer and systemic inflammation: treat the tumour and treat the host

  2014influential citation
• Biomarkers in Metastatic Colorectal Cancer: Predicting Prognosis and Therapeutic Response

  2014cites this paper
• Acquired Loss of Function of CYP2C19 in Cancer Patients: Studies to Determine the Prevalence and the Possible Molecular Mechanisms of This Genotype- Phenotype Discordance

  2014cites this paper
• Clinical pharmacology of novel anticancer drug formulations

  2013cites this paper
• Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate

  2013cites this paper
• Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet

  2013cites this paper
• Extra-Hepatic Cancer Represses Hepatic Drug Metabolism Via Interleukin (IL)-6 Signalling

  2013cites this paper
• Color Doppler ultrasound and gamma imaging of intratumorally injected 500 nm iron-silica nanoshells.

  2013cites this paper
• Nuclear receptors in the cross-talk of drug metabolism and inflammation

  2013cites this paper
• The single dose poloxamer 407 model of hyperlipidemia; systemic effects on lipids assessed using pharmacokinetic methods, and its effects on adipokines.

  2013cites this paper
• Xenobiotic sulphation and its variability during inflammation: a factor in adverse drug reactions?

  2013cites this paper
• Predicting chemotherapeutic response and toxicity in colorectal cancer

  2013cites this paper
• Maturation of cytochrome P450 3A mediated drug metabolism: Towards individualized dosing in children

  2013influential citation
• Development and clinical application of oral dosage forms of taxanes

  2013cites this paper
• Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response

  2012cites this paper
• Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation

  2012cites this paper
• Transcriptional Regulation of Human Drug‐Metabolizing Cytochrome P450 Enzymes

  2012cites this paper
• Animal Models for Studying Drug Metabolizing Enzymes and Transporters

  2012cites this paper
• Regulation of Drug Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer

  2012cites this paper
• Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma

  2012influential citation
• Critical Illness Is a Major Determinant of Midazolam Clearance in Children Aged 1 Month to 17 Years

  2012cites this paper
• Steroid regulation of drug-metabolizing cytochromes P450.

  2011cites this paper
• Role of retinoids, rexinoids and thyroid hormone in the expression of cytochrome p450 enzymes.

  2011cites this paper
• In vitro systems to predict hepatotoxicity : models based on hepatocarcinoma cell lines

  2011cites this paper
• Drug-Cytokine Interactions

  2011influential citation
• Extrahepatic Cancer Suppresses Nuclear Receptor–Regulated Drug Metabolism

  2011cites this paper
• The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer.

  2010cites this paper
• bearing an extra-hepatic tumour

  2010cites this paper
• A highly sensitive SPE- liquid/liquid extraction – RPLC analytical method for the determination of 6β-hydroxycortisol and cortisol in cancer patients' urine

  2010cites this paper
• Liver Membrane Proteome Glycosylation Changes in Mice Bearing an Extra-hepatic Tumor

  2010cites this paper
• Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

  2010cites this paper
• Comparison of the prognostic value of tumour‐ and patient‐related factors in patients undergoing potentially curative surgery for colon cancer

  2010cites this paper
• Expressions of Cytochrome P450, UDP-Glucuronosyltranferase, and Transporter Genes in Monolayer Carcinoma Cells Change in Subcutaneous Tumors Grown As Xenografts in Immunodeficient Nude Mice

  2010cites this paper
• Comparative study of increased plasma quinidine concentration in rats with glycerol- and cisplatin-induced acute renal failure.

  2009cites this paper
• Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics

  2009cites this paper
• Phosphorylation and protein–protein interactions in PXR-mediated CYP3A repression

  2009influential citation